Search by name or subject and open a reference to understand its identity and constituents.
Looking for the canine collection? Explore Animal references →
5-amino-1MQResearchers are exploring whether inhibiting NNMT could influence fat storage and cellular energy use. The potential application is metabolic health; the evidence discussed here is preclinical, so human weight-loss benefits remain unestablished.
Read referenceAdipotideAdipotide explores a different approach to body composition: targeting the blood supply of fat tissue. Preclinical findings prompted interest in metabolic applications, but kidney toxicity is an important unresolved limitation.
Read referenceAICARAICAR is studied for activating AMPK, a cellular energy sensor. Researchers examine how this pathway changes glucose uptake and the use of fats for energy; these mechanisms are not proof of improved human performance.
Read referenceAOD9604AOD9604 was designed to explore the fat-metabolism functions of a growth-hormone fragment. Human research has examined selected safety markers; demonstrating meaningful weight-management benefits is a separate question.
Read referenceAra-290ARA-290, or cibinetide, is investigated for tissue-protective signaling and symptoms associated with small-fiber neuropathy. Early human findings suggest a potential role in specific neuropathy settings, with larger studies needed to establish durable outcomes.
Read referenceBPC-157BPC-157 is studied for processes involved in tendon and connective-tissue repair, including collagen organization and cellular responses to injury. The potential application is tissue recovery, supported here by preclinical findings rather than established clinical benefits.
Read referenceCagrilintideCagrilintide targets amylin-related pathways involved in fullness and food intake. Human research has measured weight reduction, with the potential application and tolerability depending on the treatment and population studied.
Read referenceCagrilintide + SemaglutideThis named combination contains Cagrilintide, Semaglutide. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceCardiogenCardiogen is investigated for how short peptides influence heart-tissue cell renewal. Its potential relevance concerns cellular maintenance; tissue-culture findings do not establish better heart function.
Read referenceCartagenA reliable explanation starts with molecular identity. The name Cartagen needs a confirmed sequence before specific research findings or potential benefits can be attributed to it.
Read referenceCJC-1295 + Ipamorelin BlendThis named combination contains CJC-1295 Without DAC, Ipamorelin. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceCJC-1295 With DACThis long-acting GHRH analogue has been studied for sustained stimulation of growth hormone and IGF-1. The research clarifies endocrine signaling; downstream benefits for recovery or body composition require their own clinical evidence.
Read referenceCJC-1295 Without DACThis entry concerns GHRH-related signaling without the DAC modification. Understanding the precise molecule matters because published long-acting CJC-1295 results cannot be transferred directly to the non-DAC form.
Read referenceDSIPDSIP has been investigated for sleep continuity and daytime function. Small human studies offer mixed results, making sleep regulation an area of interest rather than a reliable, established benefit.
Read referenceEpithalonEpithalon is studied in telomere and telomerase biology, processes involved in cellular replication. This work informs questions about cellular aging; longer telomeres in cultured cells do not establish longer human life.
Read referenceFOXO4FOXO4-related research explores cellular senescence and cell-survival signaling. The protein FOXO4 and the engineered peptide FOXO4-DRI are different entities; confirming identity is essential before interpreting potential applications.
Read referenceGHK-CuGHK-Cu is investigated for collagen, extracellular-matrix remodeling and skin biology. These processes explain interest in skin and tissue applications, but results differ by experimental setting and cannot be transferred between topical and injectable formulations.
Read referenceGHRP-2 AcetateGHRP-2 helps researchers examine growth-hormone release and appetite signaling. Human experiments show acute hormonal and food-intake effects; these findings are different from demonstrated improvements in muscle or recovery.
Read referenceGHRP-6 AcetateGHRP-6 is explored for its effects on the growth-hormone secretagogue pathway. Research helps explain hormone-release mechanisms and their interaction with GHRH; clinical body-composition benefits cannot be inferred from cell studies.
Read referenceGlow BlendThis named combination contains BPC-157, GHK-CU, TB-500. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceGonadorelinGonadorelin reproduces the signal of GnRH, which regulates pituitary LH and FSH release. Research examines the importance of hormone pulses in reproductive physiology, rather than a universal hormone-balancing effect.
Read referenceHexarelinHexarelin is investigated in growth-hormone and CD36-related pathways. Preclinical work on cholesterol transport offers a mechanistic reason to study cardiovascular biology, without establishing clinical heart protection.
Read referenceIGF-1 LR3IGF-1 LR3 is explored for growth-factor effects on muscle-cell proliferation and differentiation. Its potential applications concern tissue-growth biology; laboratory responses do not establish safe muscle-building benefits in people.
Read referenceIpamorelinIpamorelin is investigated for ghrelin-receptor activity, growth-hormone release and gastrointestinal function. These are distinct research areas; the postoperative trial discussed below did not establish its primary recovery benefit.
Read referenceKissPeptin-10Kisspeptin-10 is studied as an upstream signal in the reproductive hormone axis. Human work shows stimulation of LH, helping researchers understand reproductive physiology without establishing a general fertility or libido benefit.
Read referenceKLOWThis named combination contains BPC-157, GHK-CU, TB-500, KPV. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
KPVKPV is investigated for inflammatory signaling in intestinal and immune cells. Its potential application concerns intestinal inflammation and barrier biology, with the cited evidence remaining preclinical.
Read referenceL-GlutathioneGlutathione participates in cellular antioxidant systems. Human oral-supplementation research has measured changes in glutathione stores; whether those changes produce meaningful health benefits requires outcome-specific evidence.
Read referenceLL37LL-37 is studied in innate immunity, cell signaling and local wound biology. Its potential wound-healing applications have reached human topical studies, with mixed findings that depend on the population and analysis.
Read referenceMelanotan-1Research on afamelanotide examines melanocortin signaling and light-related symptoms in a specific photosensitivity condition. Results for a defined implant and clinical population do not establish the benefits of other preparations.
Read referenceMelanotan-2Melanotan-2 has been explored for pigmentation and other melanocortin-mediated responses. Early human observations show several physiological effects, but do not establish safe cosmetic tanning or long-term skin benefits.
Read referenceMetabolic BlendThis named combination contains NAD+, MOTS-c, 5-amino-1MQ. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceMGFMGF-related research examines how muscle responds to mechanical stress and injury. Studies explore IGF-1 variants and cell-growth signals; these findings do not establish that externally administered MGF improves recovery.
Read referenceMOTS-cMOTS-c connects mitochondrial biology with metabolic signaling. Preclinical research explores insulin sensitivity and responses to metabolic stress, offering potential applications for study rather than established human benefits.
Read referenceNAD+NAD+ is a cofactor involved in cellular energy reactions and enzyme activity. Research examines its metabolism and related pathways; measuring NAD+ metabolites does not by itself demonstrate more energy or slower aging.
Read referenceOxytocinOxytocin research spans reproductive physiology and social signaling. Potential behavioral applications depend on context and study population; clinical trials do not support a universal improvement in bonding or social function.
Read referencePE-22-28PE-22-28 is investigated for TREK-1 channel activity and neural signaling. Preclinical findings motivate questions about mood-related pathways, but do not establish an antidepressant benefit in humans.
Read referencePEG-MGFPEG-MGF combines an MGF-related peptide concept with PEG modification. Researchers would need matching molecular specifications to evaluate persistence and biological activity; findings for non-PEG peptides are not equivalent.
Read referencePT-141PT-141, or bremelanotide, has human clinical evidence for specific desire and distress outcomes in women with hypoactive sexual desire disorder. These results concern a defined clinical setting, not a general enhancement effect.
Read referenceRetatrutideRetatrutide combines GIP, GLP-1 and glucagon receptor activity. The cited phase II trial reported weight reductions that motivate further clinical study; its findings concern a particular investigational treatment and follow-up period.
Read referenceSelankSelank is explored for GABA-related signaling and stress-response mechanisms. Preclinical gene-expression findings help explain the research interest, without establishing relief of anxiety or better focus in humans.
Read referenceSelank + SemaxThis named combination contains Selank, Semax. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceSemaglutideSemaglutide acts on the GLP-1 pathway involved in appetite and glucose regulation. Large human trials of defined medicines have demonstrated weight reduction in specified populations; the study summaries explain the magnitude, duration and limitations.
Read referenceSemaglutide + BPC-157This named combination contains Semaglutide, BPC-157. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceSemaglutide + BPC-157This named combination contains Semaglutide, BPC-157. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceSemaglutide + BPC-157This named combination contains Semaglutide, BPC-157. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceSemaxSemax is investigated for neurotrophic signaling, including BDNF and TrkB. These pathways are relevant to neuronal adaptation; the cited preclinical findings do not establish better human memory or concentration.
Read referenceSermorelinSermorelin is studied through the GHRH pathway that stimulates growth-hormone release. Human endocrine responses help explain its biology, but are not equivalent to demonstrated rejuvenation or fitness benefits.
Read referenceSnap-8SNAP-8 is explored as a topical cosmetic ingredient for expression-line appearance. Potential cosmetic effects depend on the finished formulation, and the cited supplier evidence should be distinguished from independent clinical trials.
Read referenceSS-31SS-31, or elamipretide, is investigated for mitochondrial function in specific disease settings. Its potential applications depend on the condition: the cited primary mitochondrial myopathy trial did not improve its main functional outcomes.
Read referenceSurvodutideSurvodutide combines glucagon and GLP-1 receptor activity. Research explores weight regulation and metabolic outcomes; the cited phase II findings provide context for its potential rather than a prediction for an individual.
Read referenceTB-500Full-length thymosin beta-4 is studied for cell movement and tissue-repair signaling. These pathways explain interest in recovery biology, while molecular identity and direct clinical evidence remain essential to interpreting potential applications.
Read referenceTB500 Fragmented (Short Chain)This reference concerns a short fragment related to thymosin beta-4. Molecular characterization is the starting point; potential tissue applications cannot be borrowed from studies of the full-length molecule.
Read referenceTesamorelinTesamorelin stimulates the GHRH pathway. Human studies in HIV-associated abdominal fat accumulation have measured reduced visceral fat; that specific finding should not be confused with general body-weight loss.
Read referenceTesamorelin + IpamorelinThis named combination contains Tesamorelin, Ipamorelin. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceTesamorelin + Ipamorelin BlendThis named combination contains Tesamorelin, Ipamorelin. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceThymalinThymalin is investigated for immune-cell differentiation. Laboratory findings explore maturation-related markers, which are biologically informative but do not establish fewer infections or stronger immunity in practice.
Read referenceThymosin Alpha-1Thymosin alpha-1 is investigated as an immune-modulating peptide in specific clinical conditions. Its potential depends on the setting; a large sepsis trial did not show a significant mortality benefit.
Read referenceTirzepatideTirzepatide combines GIP and GLP-1 receptor activity. Human trials have measured substantial weight reduction with specific medicines and treatment plans; individual outcomes and risks vary, and these results do not establish equivalence of other preparations.
Read referenceTirzepatide + BPC-157This named combination contains Tirzepatide, BPC-157. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceTirzepatide + BPC-157This named combination contains Tirzepatide, BPC-157. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceTirzepatide + BPC-157This named combination contains Tirzepatide, BPC-157. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
Read referenceWOLVERINEThis named combination contains BPC-157, TB500. Each constituent has a distinct molecular identity; the name of a blend does not establish a combined biological effect.
